View More Recent Stories
-
Citi Reiterates Neutral Rating on Altria (MO)
-
FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products after Extensive Scientific Review
-
Morgan Stanley Starts Altria (MO) at Equalweight
-
FDA Proposes Significant Step Toward Reducing Nicotine to Minimally or Nonaddictive Level in Cigarettes and Certain Other Combusted Tobacco Products
-
Increasing unusual option volume: INVZ MO QUBT FREY PM KULR RGTI ARQT
-
F.D.A. Tries Last-Ditch Move to Slash Nicotine Levels in Cigarettes - NYT
-
BofA Securities Upgrades Altria (MO) to Buy, 'Less of a drag'
-
Altria (MO) PT Raised to $46 at Barclays
-
Altria (MO) PT Raised to $60 at Stifel
-
Altria Group (MO) Tops Q3 EPS by 3c; offers guidance
-
Altria Group (MO) call put ratio 4.4 calls to 1 put into quarter results and outlook
-
Altria (MO) PT Raised to $48 at Citi
-
Increasing unusual call option volume: MO NGD SLQT BCE SMMT DBI BNTX ALK IBKR
-
Altria (MO) PT Raised to $57 at BofA Securities
-
Altria Group (MO) and NJOY Respond to ITC Initial Determination in Complaint Against NJOY
-
Altria Group (MO) call put ratio 1.4 calls to 1 put as share price trends higher
-
Stifel Reiterates Buy Rating on Altria (MO)
-
Altria Group (MO) Raises Quarterly Dividend 4.1% to $1.02; 7.9% Yield
-
Altria (MO) PT Raised to $44.50 at Citi
-
Altria (MO) PT Raised to $40 at CFRA
-
Altria Group (MO) Misses Q2 EPS by 3c; offers guidance
-
10 policies if Trump wins and stock implications: Jefferies
-
Will vaping continue to transform tobacco? UBS answers
-
Stifel on Altria (MO): 'NJOY Aces Menthol Application – FDA Authorizes the First Menthol E-vapor'
